Pi-Cardia (@Pi_Cardia) header
Pi-Cardia (@Pi_Cardia) profile picture

Pi-Cardia is a medical device start-up company developing a novel non-implant based catheter solution for the treatment of aortic stenosis.

Rehovot, Israel
Joined January 2021
Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)Photo by Pi-Cardia (@Pi_Cardia)
Pi-Cardia retweeted
🚨 BREAKING NEWS A major milestone for Pi-Cardia and the future of complex TAVR We are excited to announce a strategic investment by Medtronic in Pi-Cardia, marking a significant milestone in our mission to make leaflet modification a standard part of complex TAVR and expanding access to ShortCut, the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. We are grateful to our team, investors, clinical partners, physicians and everyone who has supported Pi-Cardia on this journey. We look forward to this next chapter as we work together to accelerate the adoption of ShortCut and continue advancing the future of leaflet modification. We would like to extend a sincere thanks to our investors, including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose vision, support, and commitment have helped advance Pi-Cardia's mission. Read the full press release: prnewswire.com/news-releases… @Medtronic @MDT_StructHeart @MDTVascular @Eegg34 @EyalKolka @jssoskin @SofinnovaVC @SpringEquity @jacques_seguin #PiCardia #Medtronic #TAVR #StructuralHeart #MedTech #Cardiology #Innovation
🤖 Made with AI
1
156
Pi-Cardia retweeted
Proud to share we performed first 2 Shortcut assisted VIV TAVR cases in TX this week with excellent outcome. Both leaflets split in <20 min, game changer for high surgical risk pts at high risk of coronary obstruction with VIV TAVR. Grateful for our team and hospital admin.
8
14
2
80
11,543
Pi-Cardia Shortcut FDA approved! What a great news! Best dedicated device to make the procedure simpler and more accessible! Congratulations investigators!
🚨 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦 🚨 We are thrilled to announce that 𝗣𝗶-𝗖𝗮𝗿𝗱𝗶𝗮 𝗵𝗮𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝗱 𝗙𝗗𝗔 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗦𝗵𝗼𝗿𝘁𝗖𝘂𝘁 device! 🎉 This is a huge milestone, as we believe ShortCut will be a game-changing leaflet modification solution for the lifetime management of patients with aortic stenosis, addressing coronary obstruction prior to implanting a TAVR. 🫀 Thank you to everyone for your ongoing support, collaboration, and partnership in helping us reach this great achievement! 👏🏻 The full press release can be found in the below link: businesswire.com/news/home/2… @DvirDanny @SusheelKodaliMD @didier_tchetche @MartyBLeon @PPibarot @PhilGenereuxMD @benjaminseguy @HemalGada @tnazifMD @Ryvetsprog @nicolasdumonte1 @AUnbehaun @modine_thomas @whisenant_brian @caussinchristo1 @Lenard08808061 @DrTomWaggoner @ChetcutiStan @SaibalKar @mszerlip @DanBlackman7 @KornowskiRan @paolo_denti @MarianKukucka @TernacleJ @TheLADoctor @ramii125 @Mo_A_W @PradeepYadavMD @VinodThourani @Edwards_TAVR @EdwardsLifesci @MDT_StructHeart @AbbottNews @BSCCardiology @TCTMD @PCRonline @ACCinTouch @American_Heart @TAVRBot #PiCardia #ShortCut #TAVI #TAVR #AorticValve #AorticStenosis #ValveinValve #VIV #Innovation #StructuralHeart #LifetimeManagement #LifetimeManagementofAS #percutaneoustreatment #transcatheter #leafletsplitting #medtech #startuphealth #coronaryobstruction #coronaryaccess #leafletmodification #valvefailure #mechanicalsplitting #valves #TAVRenabler
1
2
21
2,412
Lifetime management of aortic stenosis calls for leaflet modification solutions like ShortCut™ to ensure that we are carefully addressing the risk of coronary obstruction before implanting a valve businesswire.com/news/home/2…
1
11
3
65
11,955
TAV-in-TAV is coming and what a perfect time for Pi-Cardia Shortcut device to be available (hopefully soon🤞), make the leaflet modification simple, predictable, user friendly!
3
35
2,111
TAVR in TAVR is coming…will be 15% of all the TAVR performed by 2035…get your team ready! Leaflet modification of prosthetic valve and native will be crucial!
#NYValves2024 @crfheart @PhilGenereuxMD presented “Prediction Models for Bioprosthetic Valve Failure” Published @crfshj 🔹Need to plan for load of cases w physician training (imaging + IC) & streamlining cathlab (inevitable) 🔹Invitation to industry to design technologies specific for the ViV procedures 🔹Understand other THV growth as well eg TV & MV
1
11
31
4,907
#NYValves2024 @crfheart @PhilGenereuxMD presented “Prediction Models for Bioprosthetic Valve Failure” Published @crfshj 🔹Need to plan for load of cases w physician training (imaging + IC) & streamlining cathlab (inevitable) 🔹Invitation to industry to design technologies specific for the ViV procedures 🔹Understand other THV growth as well eg TV & MV
#NYValves2024 @crfheart Featured research in AV Intervention 🔹French VALVENOR Registry: age/futility & patterns of SAVR/TAVR choice 🔹Great diversity in the panel that noted global differences in practice eg Korea TAVR reimbursement for >80 & Gulf mean age 72yr 🔹Futility poorly projected ~50%
11
1
15
8,471
In a nutshell: what were the highlights in Interventions in Valvular Disease at the 2024 edition of #EuroPCR ? @CCook_MD hosts @nicolasdumonte1 and Bernard Prendergast as they discuss the key takeaways from this year's Course. Watch here ➡️pcronline.com/Cases-resource… #TAVI #TAVR #TMVR #TreatTR #FixTR
1
8
20
2,534
📢 Accepted for publication and presented today at #NYValves2024! @PhilGenereuxMD unveils a proposed model for predicting treatment of bioprosthetic aortic valve failure in the U.S. #NYValves2024. 🫀 #CardioTwitter #CardioX #CardioResearch
10
1
25
4,832
PCR Perspectives: First report of an IDE pivotal study of a dedicated splitting device during TAVR 📺 pcronline.com/Cases-resource… @CCook_MD hosts @MartyBLeon as they discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during #TAVR, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures by 2028. #TAVI #EuroPCR #interventionalcardiology #cardiotwitter #cardioX
2
9
1,537
Watch this roundtable discussion by key experts, @SusheelKodaliMD, @DvirDanny, and @PhilGenereuxMD, on how ShortCut leads the way for leaflet modification, including highlights from the pivotal study results presented at #EuroPCR 2024. #pivotalstudy Sponsored post by @Pi_Cardia

4
39
147,529
Leaflet modifiation using ShortCut was safe, achieved successful leaflet splitting in all patients. Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study academic.oup.com/eurheartj/a…
1
11
25
2,035
#EuroPCR 2024 has now officially come to an end. Thank you 🙏🏼 to the 12,100 participants who joined us for this exceptional week of learning & sharing. Safe travels back home 🚶🏼🚴🏼‍♀️🚎🚗 🚂✈️and save the date 🗓️ for the 2025 edition from 20 - 23 May! #interventionalcardiology
18
56
3,332
Danny Dvir shares findings from the #ShortCut IDE trial, assessing the use of a dedicated leaflet splitting device in 60 valve in valve TAVI patients #EuroPCR
1
1
2
297
Shortcut IDE trial: safe, effective and reproducible. No learning curve! Is this technique going to be standard practice in all valve in valve? @PCRonline #tavi #europcr #lifetimemanagement
8
29
1,503